Elliott believes GSK has a substantial value creation opportunity 45% upside in its share price ahead of Consumer Health separation and greater beyond
Despite its strengths, GSK has a poor record of operational execution and value creation, leading to scepticism…
Elliott Publishes Letter on GlaxoSmithKline
Share this article
More News
Bitcoin ETFs attract $240M despite crypto market downturn
April 11, 2026
Bitcoin nears $73K again as ETH and HYPE push higher
April 11, 2026